Healthcare Resource Use in Commercially- and Medicaid-Insured Infants, Toddlers, and Children Diagnosed With Invasive Meningococcal Disease in the United States
Moderator
Oscar A Herrera-Restrepo, PhD, GSK, Springfield, VA, United States
Speakers
Elizabeth Packnett, MPH, Merative, Washington, DC, United States; Megan Richards; Elise Kuylen, PhD, Wavre, Belgium; Tosin Olaiya; Lindsay Landgrave; Andrew G Allmon; Linda Niccolai
OBJECTIVES: To describe all-cause healthcare resource utilization (HCRU) among infants (<1 year), toddlers (1-4 years), and children (5-10 years) diagnosed with invasive meningococcal disease (IMD) in the United States (US).
METHODS: This retrospective study analyzed claims data of commercially- and Medicaid-insured individuals from 01/01/2005 to 12/31/2022. Individuals with IMD were identified through inpatient admissions with a primary IMD diagnosis and matched 1:5 with individuals without IMD. Toddlers and children were required to have six months of continuous enrollment prior to index. A variable follow-up period was used to assess all-cause HCRU, which was calculated using diagnosis/procedure codes and reported as per-patient per-month (PPPM; mean [standard deviation]).
RESULTS: In the commercial cohort (N>29.1 million), 21 infants, 19 toddlers, and 21 children diagnosed with IMD were included. In the Medicaid cohort (N>17.9 million), 115 infants, 35 toddlers, and 13 children diagnosed with IMD were included. Median follow-up length (across insurance cohort, age group, and IMD status) ranged from 244.0-1,161.0 days. Individuals with IMD had significantly longer inpatient stays than matched individuals across insurance cohorts (1.50 [3.67] vs. 0.02 [0.10] days; all p≤0.001). The number of office visits was significantly higher for individuals with IMD than matched individuals (commercial: 1.11 [0.91] vs. 0.54 [0.45] in infants, 0.46 [0.40] vs. 0.22 [0.20] in toddlers, and 0.53 [0.44] vs. 0.17 [0.25] in children; Medicaid: 0.53 [0.38] vs. 0.37 [0.40] in infants, 0.48 [0.48] vs. 0.19 [0.29] in toddlers, and 0.43 [0.32] vs. 0.14 [0.23] in children; all p<0.001). Emergency visits were significantly more common among infants with IMD than matched individuals (commercial: 0.06 [0.11] vs. 0.02 [0.04]; Medicaid: 0.12 [0.15] vs. 0.06 [0.13]; all p≤0.004).
CONCLUSIONS: Preventing IMD in early childhood may help reduce HCRU, which can be considerable, address inequalities associated with insurance, and ease financial burdens on families and healthcare systems. Funding: GSK (VEO-000995).
METHODS: This retrospective study analyzed claims data of commercially- and Medicaid-insured individuals from 01/01/2005 to 12/31/2022. Individuals with IMD were identified through inpatient admissions with a primary IMD diagnosis and matched 1:5 with individuals without IMD. Toddlers and children were required to have six months of continuous enrollment prior to index. A variable follow-up period was used to assess all-cause HCRU, which was calculated using diagnosis/procedure codes and reported as per-patient per-month (PPPM; mean [standard deviation]).
RESULTS: In the commercial cohort (N>29.1 million), 21 infants, 19 toddlers, and 21 children diagnosed with IMD were included. In the Medicaid cohort (N>17.9 million), 115 infants, 35 toddlers, and 13 children diagnosed with IMD were included. Median follow-up length (across insurance cohort, age group, and IMD status) ranged from 244.0-1,161.0 days. Individuals with IMD had significantly longer inpatient stays than matched individuals across insurance cohorts (1.50 [3.67] vs. 0.02 [0.10] days; all p≤0.001). The number of office visits was significantly higher for individuals with IMD than matched individuals (commercial: 1.11 [0.91] vs. 0.54 [0.45] in infants, 0.46 [0.40] vs. 0.22 [0.20] in toddlers, and 0.53 [0.44] vs. 0.17 [0.25] in children; Medicaid: 0.53 [0.38] vs. 0.37 [0.40] in infants, 0.48 [0.48] vs. 0.19 [0.29] in toddlers, and 0.43 [0.32] vs. 0.14 [0.23] in children; all p<0.001). Emergency visits were significantly more common among infants with IMD than matched individuals (commercial: 0.06 [0.11] vs. 0.02 [0.04]; Medicaid: 0.12 [0.15] vs. 0.06 [0.13]; all p≤0.004).
CONCLUSIONS: Preventing IMD in early childhood may help reduce HCRU, which can be considerable, address inequalities associated with insurance, and ease financial burdens on families and healthcare systems. Funding: GSK (VEO-000995).
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE80
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Pediatrics, STA: Vaccines